>
BioTelemetry Inc logo

BEAT - BioTelemetry Inc Share Price

$71.96 0.0  0.0%

Last Trade - 08/02/21

Sector
Healthcare
Size
Mid Cap
Market Cap £1.78bn
Enterprise Value £1.83bn
Revenue £316.0m
Position in Universe th / 6846
Bullish
Bearish
Unlock BEAT Revenue
Momentum
Relative Strength (%)
1m -2.59%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
166.6 178.5 208.3 286.8 399.5 439.1 445.2 508.1 +21.4%
+329 -78.1 +245.2 -22.9 +52.1 +22.0
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020,BioTelemetry Inc revenues decreased less than 1% to$326.8M. Net income decreased 43% to $16.1M. Revenuesreflect Corporate and Other segment increase of 19% to$10.8M, also reflect Helathcare segment decrease of 3% to$268.9M, Research segment decrease of 9% to $37.4M. Netincome was partially offset by General and administrativeincrease of 9% to $95.7M (expense), Other Non Rec.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BEAT Revenue Unlock BEAT Revenue

Net Income

BEAT Net Income Unlock BEAT Revenue

Normalised EPS

BEAT Normalised EPS Unlock BEAT Revenue

PE Ratio Range

BEAT PE Ratio Range Unlock BEAT Revenue

Dividend Yield Range

BEAT Dividend Yield Range Unlock BEAT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
BEAT EPS Forecasts Unlock BEAT Revenue
Profile Summary

BioTelemetry, Inc. is a remote medical technology company focused on delivery of health information. The Company is principally engaged in providing remote cardiac monitoring, centralized core laboratory services for clinical trials, remote blood glucose monitoring, and original equipment manufacturing that serves both healthcare and clinical research customers. The Company operates in two segments: Healthcare and Research. The Healthcare segment is focused on remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders and to monitor the functionality of implantable cardiac devices. It offers cardiologists, electrophysiologists and primary care physicians a full spectrum of solutions, which provides them with a single source of cardiac monitoring services. The Research segment is engaged in centralized core laboratory services providing cardiac monitoring, imaging services, scientific consulting and data management services for drug and medical device trials.

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated April 12, 2013
Public Since August 1, 2013
No. of Shareholders: 52
No. of Employees: 1,700
Sector Healthcare
Industry Healthcare Providers & Services
Index
Exchange NASDAQ Global Select Market
Shares in Issue 34,310,908
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BEAT Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BEAT
Upcoming Events for BEAT
Frequently Asked Questions for BioTelemetry Inc
What is the BioTelemetry Inc share price?

As of 08/02/21, shares in BioTelemetry Inc are trading at $71.96, giving the company a market capitalisation of £1.78bn. This share price information is delayed by 15 minutes.

How has the BioTelemetry Inc share price performed this year?

Shares in BioTelemetry Inc are currently trading at $71.96 and the price has moved by 40.25% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the BioTelemetry Inc price has moved by -4.05% over the past year.

What are the analyst and broker recommendations for BioTelemetry Inc?

Of the analysts with advisory recommendations for BioTelemetry Inc, there are there are currently 0 "buy" , 4 "hold" and 0 "sell" recommendations. The overall consensus recommendation for BioTelemetry Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will BioTelemetry Inc next release its financial results?

BioTelemetry Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the BioTelemetry Inc dividend yield?

BioTelemetry Inc does not currently pay a dividend.

Does BioTelemetry Inc pay a dividend?

BioTelemetry Inc does not currently pay a dividend.

When does BioTelemetry Inc next pay dividends?

BioTelemetry Inc does not currently pay a dividend.

How do I buy BioTelemetry Inc shares?

To buy shares in BioTelemetry Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of BioTelemetry Inc?

Shares in BioTelemetry Inc are currently trading at $71.96, giving the company a market capitalisation of £1.78bn.

Where are BioTelemetry Inc shares listed? Where are BioTelemetry Inc shares listed?

Here are the trading details for BioTelemetry Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: BEAT
What kind of share is BioTelemetry Inc?

We were not able to load our ranking data for BioTelemetry Inc

Is there a BioTelemetry Inc share price forecast 2021?

Shares in BioTelemetry Inc are currently priced at $71.96. At that level they are trading at 0.06% discount to the analyst consensus target price of 0.00.

Analysts covering BioTelemetry Inc currently have a consensus Earnings Per Share (EPS) forecast of 1.716 for the next financial year.

How can I tell whether the BioTelemetry Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioTelemetry Inc. Over the past six months, the relative strength of its shares against the market has been 36.68%. At the current price of $71.96, shares in BioTelemetry Inc are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the BioTelemetry Inc PE Ratio?

The BioTelemetry Inc PE ratio based on its reported earnings over the past 12 months is 89.55. The shares are currently trading at $71.96.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of BioTelemetry Inc?

We were unable to find the directors for BioTelemetry Inc.

Who are the major shareholders of BioTelemetry Inc?

Here are the top five shareholders of BioTelemetry Inc based on the size of their shareholding:

BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 14.47% (4.96m shares)
ArrowMark Colorado Holdings, LLC Investment Advisor/Hedge Fund
Percentage owned: 13% (4.46m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 10.81% (3.71m shares)
iShares Core S&P Small-Cap ETF Mutual Fund
Percentage owned: 6.57% (2.25m shares)
Vanguard Explorer Fund Mutual Fund
Percentage owned: 5.69% (1.95m shares)
Similar to BEAT
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.